© 2004 by Oxford University Press
© 2004 Oxford University Press
CORRESPONDENCE |
RESPONSE: Re: Playing the Old Piano: Another Tune for Endocrine Therapy
Correspondence to: Daniel F. Hayes, MD, University of Michigan Comprehensive Cancer Center, 6312 Cancer Center, 1500 East Medical Center Dr., Ann Arbor, MI 48109-0942 (e-mail: hayesdf{at}umich.edu)
It is gratifying to hear that the authors read my editorial "with interest," because one often wonders whether one's writing is noticed by others. Regardless, their observation that approximately one-third of women who are refractory to anastrozole treatment appeared to benefit from fulvestrant underscores my caution regarding the necessity of performing well-designed clinical trials to test hypotheses generated in highly stylized preclinical models. Indeed, the observation from their phase II clinical trial and observations from the preclinical models of Osipo et al. raise the idea of a subsequent controlled trial in aromatase-refractory, estrogen-receptor–rich patients: fulvestrant with or without ongoing estrogen ablation?
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||